AR085573A1 - Composiciones y metodos de inmunizacion contra el virus de la hepatitis c - Google Patents
Composiciones y metodos de inmunizacion contra el virus de la hepatitis cInfo
- Publication number
- AR085573A1 AR085573A1 ARP120101008A ARP120101008A AR085573A1 AR 085573 A1 AR085573 A1 AR 085573A1 AR P120101008 A ARP120101008 A AR P120101008A AR P120101008 A ARP120101008 A AR P120101008A AR 085573 A1 AR085573 A1 AR 085573A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- hcv
- antigens
- specificity
- antibodies
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 238000002649 immunization Methods 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 16
- 241000711549 Hepacivirus C Species 0.000 abstract 15
- 239000000427 antigen Substances 0.000 abstract 11
- 102000036639 antigens Human genes 0.000 abstract 11
- 108091007433 antigens Proteins 0.000 abstract 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 6
- 239000012634 fragment Substances 0.000 abstract 5
- 230000000890 antigenic effect Effects 0.000 abstract 4
- 230000003308 immunostimulating effect Effects 0.000 abstract 4
- 208000005176 Hepatitis C Diseases 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 238000011321 prophylaxis Methods 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 abstract 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 abstract 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 abstract 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 abstract 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 abstract 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 abstract 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 abstract 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 abstract 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 abstract 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 abstract 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 abstract 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 abstract 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 abstract 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 abstract 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 abstract 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000030741 antigen processing and presentation Effects 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Composiciones que comprenden antígenos virales y péptidos antigénicos que corresponden o derivan de proteínas del virus de la hepatitis C (HCV), o fragmentos de las mismas, fusionadas a la cadena pesada y/o liviana de anticuerpos, o fragmentos de las mismas, que son específicos de células dendríticas (DC). La presente incluye composiciones inmunoestimulantes (vacunas contra el HCV, células dendríticas presentadoras de un antígeno del HCV, etc.) y métodos para incrementar la eficacia de la presentación de antígenos del HCV por una célula presentadora de antígenos, para el tratamiento, la profilaxis o una combinación de ambos contra la hepatitis C en un sujeto humano, y métodos para proporcionar inmunoestimulación por activación de una o más células dendríticas, y métodos para tratar o prevenir la hepatitis C.Reivindicación 1: Una composición inmunoestimulante con la que puede generarse una respuesta inmune en un sujeto humano o animal, en el contexto de la profilaxis o la terapia de una infección de hepatitis C, o de una combinación de éstas, caracterizada porque comprende uno o más anticuerpos o fragmentos de anticuerpos con especificidad por las células dendríticas (DC); y uno o más antígenos del HCV unidos a los uno o más anticuerpos o fragmentos de anticuerpos. Reivindicación 2: La composición de la reivindicación 1, caracterizada porque también comprende al menos un agonista de los receptores tipo TolI (TLR) que se selecciona del grupo que consiste en los agonistas de TLR1, de TLR2, de TLR3, de TLR4, de TLR5, de TLR6, de TLR7 y de TLR8. Reivindicación 15: Una vacuna caracterizada porque comprende uno o más anticuerpos o fragmentos de anticuerpos con especificidad por las células dendríticas (DC); y uno o más antígenos del HCV unidos a los uno o más anticuerpos o fragmentos de anticuerpos, y opcionalmente un vehículo o un coadyuvante farmacéuticamente aceptable que, en combinación, es eficaz para generar una respuesta inmune en el sujeto humano o animal en el que se desea realizar la inmunoestimulación, en el contexto de la profilaxis o la terapia, o de una combinación de éstas. Reivindicación 19: La vacuna de la reivindicación 15, caracterizada porque la composición comprende un anticuerpo recombinante que comprende una proteína de fusión y uno o más antígenos del HCV hacia el extremo C de los uno o más anticuerpos o fragmentos de anticuerpos; un anticuerpo recombinante o un fragmento de un anticuerpo recombinante con especificidad por las DC y uno o más antígenos del HCV fusionados al extremo C de la cadena pesada del anticuerpo; un anticuerpo recombinante o un fragmento de un anticuerpo recombinante con especificidad por las DC y uno o más antígenos del HCV fusionados al extremo C de la cadena liviana del anticuerpo; o un anticuerpo recombinante o un fragmento de un anticuerpo recombinante con especificidad por las DC y tres antígenos o dominios antigénicos del HCV fusionados al extremo C de la cadena pesada del anticuerpo o dos antígenos o dominios antigénicos del HCV fusionados a la cadena pesada del anticuerpo y un antígeno o un dominio antigénico del HCV fusionado a la cadena liviana del anticuerpo. Reivindicación 42: Una célula dendrítica (DC) presentadora de antígenos del virus de la hepatitis C caracterizada porque comprende una o más células dendríticas (DC) aisladas, en contacto con una proteína de fusión que comprende un anticuerpo o un fragmento de anticuerpo con especificidad por las DC, donde la proteína de fusión también comprende un péptido del HCV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467840P | 2011-03-25 | 2011-03-25 | |
| US201161529700P | 2011-08-31 | 2011-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085573A1 true AR085573A1 (es) | 2013-10-09 |
Family
ID=46931875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101008A AR085573A1 (es) | 2011-03-25 | 2012-03-26 | Composiciones y metodos de inmunizacion contra el virus de la hepatitis c |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20120301465A1 (es) |
| EP (1) | EP2688592A4 (es) |
| AR (1) | AR085573A1 (es) |
| CA (1) | CA2831294A1 (es) |
| TW (1) | TW201300418A (es) |
| WO (1) | WO2012135132A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| EP2925779A1 (en) * | 2012-11-30 | 2015-10-07 | Institut Pasteur | Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock |
| JP7037884B2 (ja) * | 2014-01-13 | 2022-03-17 | ベイラー リサーチ インスティテュート | Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン |
| EP2939690A1 (en) * | 2014-04-29 | 2015-11-04 | Medizinische Hochschule Hannover | Vaccine |
| CN106659774A (zh) | 2014-05-16 | 2017-05-10 | 贝勒研究院 | 用于治疗自身免疫和炎性病症的方法和组合物 |
| CN106661119A (zh) | 2014-07-01 | 2017-05-10 | 辉瑞公司 | 双特异性异二聚化双抗体及其用途 |
| WO2016199904A1 (ja) * | 2015-06-10 | 2016-12-15 | 国立大学法人東京大学 | ワクチン用アジュバント、ワクチン、及び免疫誘導方法 |
| US11186615B2 (en) | 2015-10-08 | 2021-11-30 | The Governors Of The University Of Alberta | Hepatitis C virus E1/E2 heterodimers and methods of producing same |
| BR112018067458A2 (pt) | 2016-03-04 | 2019-01-02 | Abmuno Therapeutics Llc | anticorpos para tigit |
| KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| EP3446702A1 (en) | 2017-08-23 | 2019-02-27 | Medizinische Hochschule Hannover | Synthetic vaccine |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CA3176246A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
| CN113683684B (zh) * | 2021-06-21 | 2023-07-18 | 深圳市新产业生物医学工程股份有限公司 | 抗乙肝病毒表面抗原抗体、抗体对、含有其的检测试剂及试剂盒 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5871746A (en) | 1990-12-18 | 1999-02-16 | Institut National De La Sainte Et De La Recherche Medicale (Inserm) | Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines |
| FR2670787B1 (fr) | 1990-12-18 | 1995-06-23 | Pasteur Institut | Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins. |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| WO1993017668A1 (en) | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| DE4233152A1 (de) | 1992-10-02 | 1994-04-07 | Behringwerke Ag | Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung |
| WO1994016081A1 (de) | 1993-01-16 | 1994-07-21 | Manfred Schawaller | Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US6040137A (en) | 1995-04-27 | 2000-03-21 | Tripep Ab | Antigen/antibody specification exchanger |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| IL138809A0 (en) | 1998-04-07 | 2001-10-31 | Corixa Corp | Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same |
| AU760669B2 (en) | 1998-04-28 | 2003-05-22 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| WO2001026608A2 (en) | 1999-10-14 | 2001-04-19 | Ledbetter Jeffrey A | Dna vaccines encoding antigen linked to a domain that binds cd40 |
| US20050074465A1 (en) * | 1999-11-24 | 2005-04-07 | Michael Houghton | HCV fusion proteins with modified NS3 domains |
| DE60136334D1 (en) | 2000-02-02 | 2008-12-11 | Us Health | Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| WO2001083755A2 (en) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| AU2002211366A1 (en) | 2000-10-02 | 2002-04-15 | Chiron Corporation | Human anti-cd40 antibodies |
| WO2003029296A1 (en) | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
| US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| EP1551453A4 (en) | 2002-06-17 | 2007-04-25 | Us Gov Health & Human Serv | SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME |
| US8025873B2 (en) | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| CN100381463C (zh) | 2002-09-18 | 2008-04-16 | 中国人民解放军免疫学研究所 | 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途 |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| AU2006249305B2 (en) | 2005-05-26 | 2012-10-18 | Genentech, Inc. | Humanized anti-CD40 antibodies and their methods of use |
| BRPI0615610A2 (pt) | 2005-08-30 | 2011-05-24 | Univ Nebraska | processos e composições para vacinação de animais com antìgenos de prrsv com maior imunogenicidade |
| AU2006301846A1 (en) * | 2005-10-13 | 2007-04-19 | Akshaya Bio Inc. | Chimeric antigen containing hepatitis C virus polypeptide and FC fragment for eliciting an immune response |
| US20080241139A1 (en) | 2006-10-31 | 2008-10-02 | Regents Of The University Of Colorado | Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity |
| TWI422594B (zh) * | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| EP2115002B1 (en) | 2007-02-02 | 2014-08-20 | Baylor Research Institute | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
| US20090023822A1 (en) | 2007-07-19 | 2009-01-22 | Tijm Peter J | Method for activating and regenerating catalyst for a fischer-tropsch synthesis reaction |
| EP2307048A4 (en) * | 2008-07-16 | 2012-02-29 | Baylor Res Inst | HIV VACCINE BASED ON TARGETING OF MAXIMIZED GAG AND NEF ON DENDRITIC CELLS |
| US9562104B2 (en) | 2009-03-10 | 2017-02-07 | Baylor Research Institute | Anti-CD40 antibodies |
| TWI483734B (zh) * | 2009-09-14 | 2015-05-11 | Baylor Res Inst | 針對蘭格漢氏細胞（ｌａｎｇｅｒｈａｎｓ ｃｅｌｌｓ）之疫苗 |
| CN103153338A (zh) * | 2010-05-07 | 2013-06-12 | 贝勒研究院 | 树突细胞免疫受体（dcir）介导的人类cd8+t细胞的交叉敏化 |
-
2012
- 2012-03-26 EP EP12765865.6A patent/EP2688592A4/en not_active Withdrawn
- 2012-03-26 TW TW101110421A patent/TW201300418A/zh unknown
- 2012-03-26 US US13/430,206 patent/US20120301465A1/en not_active Abandoned
- 2012-03-26 CA CA2831294A patent/CA2831294A1/en not_active Abandoned
- 2012-03-26 AR ARP120101008A patent/AR085573A1/es unknown
- 2012-03-26 WO PCT/US2012/030593 patent/WO2012135132A1/en active Application Filing
-
2014
- 2014-01-10 US US14/152,448 patent/US9885017B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2688592A1 (en) | 2014-01-29 |
| US9885017B2 (en) | 2018-02-06 |
| US20140199763A1 (en) | 2014-07-17 |
| EP2688592A4 (en) | 2015-07-22 |
| TW201300418A (zh) | 2013-01-01 |
| CA2831294A1 (en) | 2012-10-04 |
| WO2012135132A1 (en) | 2012-10-04 |
| US20120301465A1 (en) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085573A1 (es) | Composiciones y metodos de inmunizacion contra el virus de la hepatitis c | |
| Henriques et al. | Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge | |
| Greenwood et al. | Vaccination against foot-and-mouth disease virus using peptides conjugated to nano-beads | |
| CN110279853A (zh) | 包含聚合载体货物复合物和至少一种蛋白或肽抗原的药物组合物 | |
| SI2280721T1 (en) | IMUNOTHERAPY BASED ON INDOLEAMINE 2,3-DIOXYGENESIS | |
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| JP7275185B2 (ja) | 方法 | |
| RU2014140108A (ru) | Комбинированная вакцина pcv/mycoplasma hyopneumoniae/prrs (pcv/mycoplasma hyopneumoniae/prr combination vaccine) | |
| AU2013332272B2 (en) | Improved human herpesvirus immunotherapy | |
| EA201590597A1 (ru) | Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина | |
| Valkenburg et al. | Protection by universal influenza vaccine is mediated by memory CD4 T cells | |
| Reginald et al. | Development of peptide vaccines in dengue | |
| US20230330207A1 (en) | Cancer treatment utilizing pre-existing microbial immunity | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| JP2014502961A5 (es) | ||
| AR109538A1 (es) | Vacuna contra la gripe porcina | |
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| JP2017509642A (ja) | 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬 | |
| Matsuo et al. | CD11c-specific bio-nanocapsule enhances vaccine immunogenicity by targeting immune cells | |
| Seesen et al. | A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells | |
| RU2013135148A (ru) | Полиэпитопные иммуногенные полипептиды и способы их применения | |
| MX2019006244A (es) | Construcciones de vectores virales para la expresion de adyuvantes geneticos que activan la ruta sting. | |
| Yan et al. | A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against Her2 positive B16 melanoma in mice | |
| Schotsaert et al. | Christina Lisk 1, Rachel Yuen 2, Jeff Kuniholm 2, Danielle Antos 3, Michael L. Reiser4 and Lee M. Wetzler 1, 2 | |
| WO2022226049A9 (en) | A vaccine adjuvant for infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |